Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy - Wikidata - awgldk - TriplyDB

Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy

Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy

http://www.wikidata.org/entity/Q33785074

about

Targeting Th17 Cells with Small Molecules and Small Interference RNA Hypomorphic A20 expression confers susceptibility to psoriasis.Secukinumab.Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.Pharmacological therapy of spondyloarthritis.Secukinumab: a review in moderate to severe plaque psoriasis.Pain in autoimmune disorders.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis.

P2860

Q26770523-F070AAD2-2B15-46B0-803A-46A1F53313F9 Q33848572-9E24C17A-1FCA-401B-A168-519F4542ABCB Q36391509-29E096DE-2BDF-411A-927A-2DCFBDA2592D Q37485709-F9ECBE9D-4A31-4742-AE67-B2350EDF4019 Q37717732-D4CF76EE-41A1-4605-A084-AA3393D11FFB Q38527552-C02F0B5C-3004-436E-AD0E-E66A64D190B2 Q38552526-79F81EF2-C781-4E34-881C-D107E32AA4B3 Q38905689-4CA09A94-C032-4C77-BAA7-1EAFFD7AE977 Q38969036-F13AC2CC-EF63-4328-A378-77B08E54B8F7 Q38970666-684A3559-67CB-4EA8-8DD3-10E0A84871DE Q39264020-C0F32871-1607-41DB-AF2F-D5DA2623BD2D Q50436409-0FD894C5-A92E-411A-AC2C-18DA084DCEC7

P2860

Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy

http://www.wikidata.org/entity/Q33785074

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of secukin ...... nd psoriatic arthritis therapy

@ast

Efficacy and safety of secukin ...... nd psoriatic arthritis therapy

@en

type

label

Efficacy and safety of secukin ...... nd psoriatic arthritis therapy

@ast

Efficacy and safety of secukin ...... nd psoriatic arthritis therapy

@en

prefLabel

Efficacy and safety of secukin ...... nd psoriatic arthritis therapy

@ast

Efficacy and safety of secukin ...... nd psoriatic arthritis therapy

@en

P1433

Q33785074-D7512DE3-E29E-48C0-85C6-C99AE011582E

P1476

Q33785074-8DC5425F-4F11-484F-BFA8-E318465B787B

P2093

Q33785074-2245E7D1-388A-4514-8ABC-993F98AA07EB

Q33785074-4989808B-DE34-4E40-AC29-37EBD660BFEE

P2860

Q33785074-109CE3A6-C00B-4147-A784-75182DF3B212

Q33785074-1342C301-C098-4AFF-A8D3-F3CEC8320094

Q33785074-2480180F-E818-4640-BFC6-86C8B1A94B49

Q33785074-5496254F-CF48-4358-B072-27B3E50162EB

Q33785074-69E941C8-BB56-4D88-A097-21A070F58EA6

Q33785074-6E42DDD4-413A-4EC9-A393-101E102FA30E

Q33785074-70F9C57F-D83E-4F95-9FE0-68CA6F588114

Q33785074-77BE3181-93CB-4B45-924C-04792CED660E

Q33785074-79C8DF62-90CE-42DB-BBA0-3F7AF3FB25E4

Q33785074-7CEB60A2-3D2D-40F5-9DCA-694654A4F124

P2888

Q33785074-E87AAC8F-F125-4B09-A1B6-8D96028BC314

P304

Q33785074-94AFA68A-CCF3-4926-8BFB-5E7A052E0D36

P31

Q33785074-F521522D-4952-4519-A47B-C72A7BFFF36A

P356

Q33785074-2FC5EA4B-5353-49C2-AC7A-D564817EC58D

P433

Q33785074-42E44F06-27F7-4617-AF2D-9407B2DB8D97

P478

Q33785074-7EA2B4F6-66ED-48F4-BD43-A2C06B4932AF

P50

Q33785074-97B6D9BB-B845-47A8-ACAA-22B9BBDC2C88

P577

Q33785074-44EE20D8-356E-4264-A8CC-5D90FFF64912

P5875

Q33785074-90B02D17-F9FA-4902-A357-4026BDC1F022

P6179

Q33785074-5ADD9047-68E8-4857-8E63-4D7E0D850515

P698

Q33785074-56D0DD8C-8645-4CF8-9695-5EA7D38AB763

P932

Q33785074-8B37747D-4195-428F-9A50-32C74DDFBCC7

P356

S13555-014-0042-5

P1433

Dermatology and therapy

P1476

Efficacy and safety of secukin ...... nd psoriatic arthritis therapy

@en

P2093

Camilla Dalle Vedove

http://www.w3.org/2001/XMLSchema#string

Giampiero Girolomoni

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Structure and signalling in the IL-17 receptor family

Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection.

Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.

Emerging role of IL-17 in atherosclerosis.

Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.

TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis.

Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis

Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.

Association of cardiovascular and metabolic disease genes with psoriasis

P2888

s13555-014-0042-5

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13555-014-0042-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259877436

http://www.w3.org/2001/XMLSchema#string

P6179

1036062193

http://www.w3.org/2001/XMLSchema#string

P698

24452484

http://www.w3.org/2001/XMLSchema#string

P932

4065277

http://www.w3.org/2001/XMLSchema#string